DE (CLOV)

Role: CEO, Medicare Advantage
Signature: /s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso
Issuer symbol: CLOV
Transactions as of: 13 Sep 2024
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 16 Sep 2025, 17:00:30 UTC
Date Of Original Report: 17 Sep 2024
Previous filing: 08 Jul 2024
Next filing: 07 Oct 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Reynoso Jamie L.	CEO, Medicare Advantage	C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON	/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso	16 Sep 2025	0001839066

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLOV	Class A Common Stock	Award	$0	+518,000	+26%	$0.000000	2,531,545	13 Sep 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"), each representing a right to a share of Class A Common Stock, earned in connection with the determination of the level of performance achievement in satisfaction of vesting conditions underlying a performance-based restricted share unit grant awarded on October 31, 2023. One-half of the number of earned restricted stock units vested and were settled on September 13, 2024, and the remaining one-half of the restricted stock units will vest on October 31, 2025, subject to the Reporting Person's continued employment on such vesting date. This Amendment is being filed solely to reflect the full number of RSUs that were achieved.
F2	Number reflects total directly held Class A Common Stock taking into account the amended number and subsequent transactions through September 15, 2024.

Content

Represents restricted stock units ("RSUs"), each representing a right to a share of Class A Common Stock, earned in connection with the determination of the level of performance achievement in satisfaction of vesting conditions underlying a performance-based restricted share unit grant awarded on October 31, 2023. One-half of the number of earned restricted stock units vested and were settled on September 13, 2024, and the remaining one-half of the restricted stock units will vest on October 31, 2025, subject to the Reporting Person's continued employment on such vesting date. This Amendment is being filed solely to reflect the full number of RSUs that were achieved.

Number reflects total directly held Class A Common Stock taking into account the amended number and subsequent transactions through September 15, 2024.